Location of Repository

Characterization of Mycobacterium sp. P450 Systems

By David Geraint Lewis

Abstract

This work reports detailed structural and mechanistic characterisation of three cytochrome P450 (CYP) enzymes from diverse mycobacteria.\ud For Mycobacterium tuberculosis (Mtb) CYP121, a high resolution atomic structure revealed mutagenesis targets to explore structure/function relationships. Several mutants were generated and structurally characterised. The R386L variant disrupted heme coordination environment, producing an enzyme with shifted Soret absorption features and predominantly high-spin ferric heme iron. EPR and resonance Raman spectra confirmed the spin-state conversion. The P346L variant resulted in altered heme conformation due to perturbed interactions with the heme pyrrole D ring. Alterations to heme ligation state were observed from EPR studies. Ligand binding and thermodynamic studies were done on CYP121 mutants. Studies of the action of various azole based drugs (which bind tightly to CYP121 heme iron) showed that azoles had potent inhibitory effects on Mtb growth.\ud Mycobacterium ulcerans, the aetiological agent of Buruli ulcer, produces a human toxin (mycolactone) and encodes CYP140A2 on a plasmid, with the CYP140A2 gene adjacent to other mycolactone biosynthetic genes. Purified oxidised CYP140A2 has a Soret absorption band at 418 nm and α/β bands at 567/534 nm, respectively. The Fe(II)CO complex conforms to typical P450 properties, with a characteristic Soret shift to 449 nm. Resonance Raman and EPR spectra confirm the protein to be low-spin and with a typical cysteinate- and water-ligated b-type heme iron. Azole drugs were shown to bind CYP140A2 tightly, and to be potential therapeutics. CYP140A2 catalysed hydroxylation of mycolactone precursor molecules, consistent with its proposed role in synthesis of the toxic polyketide.\ud Mycobacterium sp HE5 CYP151A2 was shown to have a role in metabolism of secondary amines, such as morpholine. CYP151A2 was expressed and purified, and spectroscopic analyses were consistent with cysteinate- and aqua-ligated heme iron. Dithionite reduction of CYP151A2 induced non-standard spectral changes, with a blue-shifted Soret band indicative of a cysteine thiolate-to-thiol switch in heme ligation. Thiolate coordination was restored on oxidation of CYP151A2, indicating that the thiol is readily deprotonated to thiolate in the ferric form. An 419 of 186 mM-1 cm-1 was determined for oxidised CYP151A2 and (at high concentration) morpholine substrate was shown to coordinate heme iron as an inhibitor at high concentrations

Publisher: University of Leicester
Year: 2007
OAI identifier: oai:lra.le.ac.uk:2381/3994

Suggested articles

Preview

Citations

  1. (2001a) Global trends in resistance to antituberculosis drugs.
  2. (2002b) Covalent attachment of the heme prosthetic group in the CYP4F cytochrome p450 family.
  3. (1996). 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
  4. (1998). A close family resemblance: the importance of structure in understanding cytochromes
  5. (1989). A Conserved Residue of Cytochrome-P-450 Is Involved in Heme-Oxygen Stability and Activation.
  6. (2001). A cytochrome P450 and a ferredoxin isolated from Mycobacterium sp. strain HE5 after growth on morpholine.
  7. (1997). A direct electrode-driven P450 cycle for biocatalysis.
  8. (2001). A fast and efficient metalmediated oxidation of isoniazid and identification of isoniazid - NAD(H) adducts.
  9. (2000). A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells.
  10. (1962). A New Cytochrome in Liver Microsomes.
  11. (1991). A New Pathway for Isonicotinate Degradation by Mycobacterium Sp Ina1.
  12. (1997). A new triazole, voriconazole (UK109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
  13. (2005). A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin.
  14. (2002). A novel class of self-sufficient cytochrome P450 monooxygenases in prokaryotes.
  15. (2005). A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase.
  16. (2002). A novel sterol 14 alpha-demethylase/ferredoxin fusion protein (MCCYP51FX) from Methylococcus capsulatus represents a new class of the cytochrome P450 superfamily.
  17. (2005). A rapid method of diagnosing pulmonary tuberculosis using stir bar sorptive extraction-thermal desorption-gas chromatography-mass spectrometry.
  18. (2006). A reference database for circular dichroism spectroscopy covering fold and secondary structure space.
  19. (2003). A self-sufficient peroxide-driven hydroxylation biocatalyst.
  20. (2000). A single amino acid substitution (F363I) converts the regiochemistry of the spearmint (-)-limonene hydroxylase from a C6- to a C3-hydroxylase.
  21. (2000). A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
  22. (2004). A survey of active site access channels in cytochromes P450.
  23. (1976). A thermodynamic model of regulation: modulation of redox equilibria in camphor monoxygenase.
  24. (1996). Aconitase as iron-sulfur protein, enzyme, and iron-regulatory protein.
  25. (1997). Active site analysis of P450 enzymes: Comparative magnetic circular dichroism spectroscopy. Archives of biochemistry and biophysics.
  26. (1995). Active-Site Analysis of Ferric P450 Enzymes -Hydrogen-Bonding Effects on the Circular-Dichroism Spectra.
  27. (2001). Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.
  28. (2000). Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.
  29. (2007). Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
  30. (1975). Activity of rifampicin on Mycobacterium ulcerans."
  31. (2002). Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland.
  32. (1992). Aerobic vinyl chloride metabolism in Mycobacterium aurum L1.
  33. (1996). ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex.
  34. (2001). Alanine-scanning of the 50's loop in the Clostridium beijerinckii flavodoxin: Evaluation of additivity and the importance of interactions provided by the main chain in the modulation of the oxidation-reduction potentials.
  35. (1980). Aliphatic alcohols improve the adsorptive performance of cellulose nitrate membranes--application in chromatography and enzyme assays. Analytical biochemistry.
  36. (2002). Allosteric mechanisms in P450eryF probed with 1-pyrenebutanol, a novel fluorescent substrate. Biochemical and biophysical research communications.
  37. (2005). Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole.
  38. (1992). Amines (Lower aliphatic),
  39. (2000). An A245T mutation conveys on cytochrome P450eryF the ability to oxidize alternative substrates. The Journal of biological chemistry.
  40. (1993). An Accuracy Center in the Ribosome Conserved over 2 Billion Years.
  41. (2004). An electrostatically driven conformational transition is involved in the mechanisms of substrate binding and cooperativity in cytochrome P450eryF.
  42. (2006). An explosive-degrading cytochrome P450 activity and its targeted application for the phytoremediation of RDX.
  43. (1992). An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.
  44. (1990). An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of Saccharopolyspora erythraea.
  45. (2005). Analysis of the nearly identical morpholine monooxygenase-encoding mor genes from different Mycobacterium strains and characterization of the specific NADH: ferredoxin oxidoreductase of this cytochrome P450 system.
  46. (1997). Analysis of the oxyRahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrobial Agents and Chemotherapy.
  47. (1988). Antibodies:
  48. (2003). Antifungal agents: mechanisms of action.
  49. (1998). Antifungals: mechanism of action and resistance, established and novel drugs.
  50. (1988). Antigenic relationship between Mycobacterium paratuberculosis and Mycobacterium avium.
  51. (1996). Antimicrobial agents: In vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids. In: Antibiotics in Laboratory Medicine.
  52. (1999). Antitubercular activities of certain antifungal and antihelminthic drugs. Tuber Lung Dis.
  53. (2002). Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review. Arch Pharm (Weinheim).
  54. (1991). Antituberculosis drugs: antimicrobial activity in vitro.
  55. (1958). Application of a Theory of Enzyme Specificity to Protein Synthesis.
  56. (2002). Aquatic insects as a vector for Mycobacterium ulcerans.
  57. (1996). Assignment of protoheme Resonance Raman spectrum by heme labeling in myoglobin.
  58. (2003). Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450.
  59. (2002). Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family.
  60. (1999). Automated MAD and MIR structure solution. Acta Crystallographica.
  61. (2007). Axial coordination of heme in ferric CcmE chaperone characterized by EPR spectroscopy.
  62. (2002). Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes.
  63. (2001). Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.
  64. (2002). Azotobacter vinelandii ferredoxin I - A sequence and structure comparison approach to alteration of [4Fe-4S]2(+/+) reduction potential.
  65. (1999). Bacteria designed for bioremediation.
  66. (1996). Bacterial cytochromes P-450.
  67. (1995). Bacterial P450s: structural similarities and functional differenced,
  68. (2003). Bactericidal activity of riframpicin and streptomycin treatment for early huyman M. ulcerans lesions.
  69. (2000). Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.
  70. (1997). Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria.
  71. (2003). Biodegradation of cyclic amines by a Pseudomonas strain involves an amine mono-oxygenase.
  72. (2000). Biodegradation of nitroaromatic compounds and explosives. Boca Raton, Fla:
  73. (2006). Biophysical characterization of the sterol demethylase P450 from Mycobacterium tuberculosis, its cognate ferredoxin, and their interactions.
  74. (2002). Biotechnology and bioremediation: successes and limitations.
  75. (1971). Buruli disease in a district of Uganda.
  76. (2002). Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis.
  77. (2004). Buruli ulcer in the Democratic Republic of Congo: epidemiology, presentation and outcome.
  78. (1987). Buruli ulcer--necrotizing infection of the hand of a plastic surgeon.
  79. (1994). C-terminal region of adrenodoxin affects its structural integrity and determines differences in its electron transfer function to cytochrome P450.
  80. (1994). C.in Tuberculosis: Pathogenesis, Protection, and Control
  81. (1964). Carbon Monoxide-Binding Pigment of Liver Microsomes.I. Evidence for Its Hemoprotein Nature.
  82. (2004). Carotenoid hydroxylation - P450 finally! Trends in Plant Science. 9, 515-517 Institut Pasteur, Mycobacterium ulcerans (http://www.pasteur.fr/recherche/unites/Lgmb/mycogenomics.html#ulcerans) (accessed
  83. (1997). Cell biology and molecular basis of denitrification.
  84. (1998). Characterisation of flavodoxin NADP+ oxidoreductase and flavodoxin: Key components of electron transfer in Escherichia coli.
  85. (1999). Characterization and catalytic properties of the sterol 14 alpha-demethylase from Mycobacterium tuberculosis.
  86. (1995). Characterization by electron paramagnetic resonance of the interactions of L-arginine and Lthiocitrulline with the heme cofactor region of nitric oxide synthase. The Journal of biological chemistry.
  87. (1986). Characterization of a Catalytically Self-Sufficient 119,000-Dalton Cytochrome-P-450 Monooxygenase Induced by Barbiturates in Bacillus-Megaterium.
  88. (2004). Characterization of a Mycobacterium ulcerans-like infection in a colony of African tropical clawed frogs (Xenopus tropicalis).
  89. (2002). Characterization of an unusual Mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans.
  90. (1996). Characterization of endothelial nitricoxide synthase and its reaction with ligand by electron paramagnetic resonance spectroscopy.
  91. (1996). Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities.
  92. (1997). Characterization of Saccharomyces cerevisiae CYP61, sterol Delta(22)-desaturase, and inhibition by azole antifungal agents.
  93. (1996). Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: Restricted array of mutations associated with drug resistance.
  94. (1993). Characterization of the KatG Gene Encoding a Catalase-Peroxidase Required for the Isoniazid Susceptibility of Mycobacterium-Tuberculosis.
  95. (1989). Chemical Basis of Rough and Smooth Variation in Mycobacteria.
  96. (2007). Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
  97. (1991). Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance.
  98. (1999). Circular dichroism studies of flavoproteins,
  99. (1999). Cloning and characterization of the genes encoding a cytochrome P450 (PipA) involved in piperidine and pyrrolidine utilization and its regulatory protein (PipR) in Mycobacterium smegmatis mc(2)155.
  100. (2004). Cloning and enhanced expression of the cytochrome P450nor gene (nicA; CYP55A5) encoding nitric oxide reductase from Asperillgus oryzae).
  101. (1992). Cloning, Nucleotide-Sequence Determination and Expression of the Genes Encoding Cytochrome P450Soy (Soyc) and Ferredoxinsoy (Soyb) from Streptomyces-Griseus.
  102. (2004). Cofactor-apoprotein hydrogen bonding in oxidized and fully reduced flavodoxin monitored by trans-hydrogen-bond scalar couplings.
  103. (2005). Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans.
  104. (1979). Comparative-Study of 2 Highly Purified Forms of Liver Microsomal Cytochrome-P-450 - Circular-Dichroism and Other Properties.
  105. (1993). Complete assignment of cytochrome c resonance Raman spectra in enzymatic reconstitution with isotopically labeled hemes.
  106. (2001). Complete structure of the mycolactones.
  107. (2002). Complex formation of cytochrome P450cam with Putidaredoxin.
  108. (2000). Conformational energetics of a reverse turn in the Clostridium beijerinckii flavodoxin is directly coupled to the modulation of its oxidation-reduction potentials.
  109. (1994). Consequences of Oxidation in Nonplanar Porphyrins - Molecular-Structure and Diamagnetism of the Pi-Cation-Radical of Copper(Ii) Octaethyltetraphenylporphyrin.
  110. (2003). Conservation and cloning of CYP51: a sterol 14 alpha-demethylase from Mycobacterium smegmatis.
  111. (2000). Converting a c-type to a btype cytochrome:
  112. (1998). Coordination sphere versus protein environment as determinants of electronic and functional properties of iron-sulphur proteins.
  113. (2000). Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 Mycobacterium tuberculosis clinical isolates.
  114. (1976). Coupling of spin, substrate, and redox equilibria in cytochrome P450.
  115. (2004). Crystal structure of biotin synthase, an S-adenosylmethionine-dependent radical enzyme.
  116. (2001). Crystal structure of cytochrome P450 14 alpha-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors,
  117. (2001). Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors.
  118. (2006). Crystal structure of human cytochrome P450 2D6.
  119. (2002). Crystal Structure of Oxyb, a Cytochrome P450 Implicated in an Oxidative Phenol Coupling Reaction During Vancomycin Biosynthesis.
  120. (2003). Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis.
  121. (2004). Crystal structure of P450cin in a complex with its substrate, 1,8-cineole, a close structural homologue to D-camphor, the substrate for P450cam.
  122. (2006). Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode.
  123. (2003). Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK.
  124. (2000). Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity,
  125. (1997). Crystallisation and preliminary diffraction and electron paramagnetic resonance studies of a single crystal of cytochrome P450 nor,
  126. (2000). Crystallisation and preliminary X-ray diffraction analysis of a cytochrome P450 (CYP119) form Solfolobus solfataricus,
  127. (2002). Crystallographic investigation of the role of aspartate 95 in the modulation of the redox potentials of Desulfovibrio vulgaris flavodoxin.
  128. (1994). CrystalStructure and Refinement of Cytochrome P450(Terp) at 2-Center-Dot-3 Angstrom Resolution.
  129. (1997). Current developments in antibacterial and antifungal chemotherapy. Drug News and Perspectives.
  130. (2004). Current status of treatment completion and fatality among tuberculosis patients in Spain.
  131. (2006). CYP153A6, a soluble P450 oxygenase catalyzing terminal-alkane hydroxylation.
  132. (1998). CYP51-like gene of Mycobacterium tuberculosis actually encodes a P450 similar to eukaryotic CYP51.
  133. (1989). Cytochrome P-450, reductive metabolism, and cell injury. Drug metabolism review.
  134. (1998). Cytochrome P450 monooxygenases.
  135. (2001). Cytochrome P450 pattern revision.
  136. (2002). Cytochrome P450(cin) (CYP176A), isolation, expression, and characterization. The Journal of biological chemistry.
  137. (1974). Cytochrome P450Cam.1. Crystallization and Properties.
  138. (1989). Cytochrome-C at Charged Interfaces .2. Complexes with Negatively Charged Macromolecular Systems Studied by Resonance Raman-Spectroscopy.
  139. (1991). Cytochrome-P-450 - Multiplicity of Isoforms, Substrates, and Catalytic and Regulatory Mechanisms.
  140. (1992). Cytokine Production Induced by Mycobacterium-Tuberculosis Lipoarabinomannan - Relationship to Chemical-Structure.
  141. (1987). Dechlorination and para-hydroxylation of polychlorinated phenols by Rhodococcus chlorophenolicus.
  142. (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
  143. (1999). Decreased electron transfer rates of manganese porphyrins with conformational distortion of the macrocycle. Angewandte Chemie-International Edition.
  144. (1988). Degradation and Omethylation of chlorinated phenolic compounds by Rhodococcus and Mycobacterium strains.
  145. (1998). Degradation of morpholine by an environmental Mycobacterium strain involves a cytochrome P-450.
  146. (1994). Degradation of morpholine by Mycobacterium aurum MO1.
  147. (1996). Degradation of pyrene by Mycobacterium flavescens.
  148. (1985). Destruction of morpholine by fixed bacteria.
  149. (1997). Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease.
  150. (1993). Detection of Rifampicin-Resistance Mutations in MycobacteriumTuberculosis.
  151. (2001). Determinants of drug-resistant tuberculosis: analysis of 11 countries.
  152. (1995). Determinants of the Vinyl Stretching Frequency in Protoporphyrins - Implications for Cofactor-Protein Interactions in Heme-Proteins.
  153. (1978). Determination of oxidation-reduction potentials,
  154. (2001). Determination of the redox properties of human NADPH-cytochrome P450 reductase.
  155. (1955). Detoxication of Drugs and Other Foreign Compounds by Liver Microsomes.
  156. (1995). Diagnostic Instrument Systems;
  157. (1987). Dietary intakes of nitrosamines precursors.
  158. (2006). Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
  159. (1977). DNA sequencing with chain-terminating inhibitors.
  160. (1992). Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization.
  161. (1994). Dormancy of Mycobacterium tuberculosis and latency of disease.
  162. (2004). Drug resistant tuberculosis soars in eastern Europe.
  163. (1995). Drug-Resistance in Mycobacterium-Tuberculosis.
  164. (2002). Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Current pharmaceutical biotechnology.
  165. (1979). Effect of Sulfolipid-I on Trehalose-6,6'-Dimycolate (Cord Factor) Toxicity and Anti-Tumor Activity. Infection and Immunity.
  166. (1981). Effects of chaotropic and antichaotropic agents on elution of poliovirus adsorbed on membrane filters.
  167. (1998). Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system.
  168. (1995). Effects of Low-Doses of N-Nitrosomorpholine on the Development of Early Stages of Hepatocarcinogenesis.
  169. (1999). Effects of mutations in aspartate 14 on the spectroscopic properties of the [Fe3S4](+,0) clusters in Pyrococcus furiosus ferredoxin.
  170. (1998). Effects of various imidazole ligands on heme conformation in endothelial nitric oxide synthase.
  171. (2004). Efflux-mediated drug resistance in bacteria.
  172. (2003). Electrochemistry of P450cin: new insights into P450 electron transfer. Chemical Communications
  173. (1995). Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire.
  174. (2000). Engineering bacteria for bioremediation.
  175. (1999). Engineering cytochrome c peroxidase into cytochrome P450: The proximal effect on heme-thiolate ligation.
  176. (2000). Engineering microsomal cytochrome P4502C5 to be a soluble, monomeric enzyme - Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding.
  177. (2003). Engineering of a water-soluble plant cytochrome P450, CYP73A1, and NMR-based orientation of natural and alternate substrates in the active site. Plant Physiology.
  178. (2002). Enzymatic reaction of hydrogen peroxide-dependent peroxygenase cytochrome P450s: Kinetic deuterium isotope effects and analyses by resonance Raman spectroscopy.
  179. (1995). Epidemiology of Mycobacterial Diseases.
  180. (1971). Epidemiology of Mycobacterium-Ulcerans Infection (Buruli Ulcer) at Kinyara,
  181. (2004). EpoK, a cytochrome P450 involved in biosynthesis of the anticancer agents epothilones A and B. Substrate-mediated rescue of a P450 enzyme.
  182. (1998). Epoxidation of olefins by cytochrome P450: Evidence from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant.
  183. (2000). Essential role for cholesterol in entry of mycobacteria into macrophages.
  184. (1999). Estimation of the number of helical and strand segments in proteins using CD spectroscopy.
  185. (1997). Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations.
  186. (1999). Evaluation of a bacteriophagebased assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
  187. (1981). Evaluation of a Rapid Radiometric Method for Drug Susceptibility Testing of Mycobacterium-Tuberculosis.
  188. (2002). Evaluation of norcarane as a probe for radicals in cytochome P450-and soluble methane monooxygenase-catalyzed hydroxylation reactions.
  189. (1986). Evaluation of streptomycin and ethambutol concentrations for susceptibility testing of Mycobacterium tuberculosis by radiometric and conventional procedures.
  190. (1985). Evaluation of the BACTEC radiometric method for detection of 1% resistant populations of Mycobacterium tuberculosis.
  191. Evidence for protein-specific interactions involving the proximal thiolate ligand.
  192. (1990). Evidence for the Presence of a Phosphatidylinositol Anchor on the Lipoarabinomannan and Lipomannan of Mycobacterium-Tuberculosis.
  193. (1998). Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res.
  194. (1993). Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection.
  195. (1999). Experimental evidence for the role of buried polar groups in determining the reduction potential of metalloproteins: the S79P variant of Chromatium vinosum HiPIP.
  196. (1993). Expression of the Core Lipopeptide of the Glycopeptidolipid Surface-Antigens in Rough Mutants of Mycobacterium avium.
  197. (2001). Expression, purification and characterization of cytochrome P450 Biol: a novel P450 involved in biotin synthesis in Bacillus subtilis.
  198. (2002). Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis.
  199. (2000). Expression, purification, and characterization of biol: A carbon-carbon bond cleaving cytochrome P450 involved in biotin biosynthesis in Bacillus subtilis.
  200. (1986). Factors influencing redox potentials of electron transfer proteins.
  201. (1999). Flavocytochrome P-450 BM3: a paradigm for the analysis of electron transfer and its control in the P-450s. Biochem Soc Trans.
  202. (2004). Flavocytochrome P450BM3 mutant A264E undergoes substrate-dependent formation of a novel heme iron ligand set.
  203. (2006). Flavodoxins: sequence, folding, binding, function and beyond.
  204. (1995). Fluidity of the Lipid Domain of Cell-Wall from Mycobacterium chelonae.
  205. (1999). Forty years of cytochrome P450.
  206. (1999). Forty years of genetics with Streptomyces: from in vivo through in vitro to in silico.
  207. (2000). Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics.
  208. (1998). Further characterization of hydrogen peroxide dependent fatty acid alpha-hydroxylase from Sphingomonas paucimobilis.
  209. (1993). Further Structural Definition of a New Family of Glycopeptidolipids from Mycobacterium xenopi.
  210. (2000). Fusarium oxysporum fatty-acid subterminal hydroxylase (CYP505) is a membrane-bound eukaryotic: Counterpart of Bacillus megaterium cytochrome P450BM3.
  211. (2000). Genetics of drug resistance in Mycobacterium tuberculosis.
  212. (2000). Genome-wide expression patterns in Saccharomyces cerevisiae: Comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol.
  213. (2000). Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tubercle and Lung Disease.
  214. (2000). Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: Implications for rapid susceptibility testing. Antimicrobial Agents and Chemotherapy.
  215. (1997). Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level.
  216. (1993). Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory.
  217. (2004). Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans.
  218. (1981). Glass capillary gas chromatography of secondary amines in foods with flame photometric detection after derivatization with benzenesulfonyl chloride.
  219. (2002). Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains.
  220. (2002). Great metalloclusters in enzymology.
  221. (2000). Haloalkane-utilizing Rhodococcus strains isolated from geographically distinct locations possess a highly conserved gene cluster encoding haloalkane catabolism.
  222. (1984). Heme enzyme structure and function. Peptide and Protein Review.
  223. (1995). Heme- thiolate proteins different from cytochromes P450 catalyisng monooxyganations,
  224. (1997). Hemecoordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation. Archives of biochemistry and biophysics.
  225. (2003). Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.
  226. (2000). High morpholine degradation rates and formation of cytochrome P450 during growth on different cyclic amines by newly isolated Mycobacterium sp strain HE5.
  227. (1987). High-Resolution Crystal-Structure of Cytochrome-P450Cam.
  228. (2003). High-resolution structure of the soluble, respiratory-type Rieske protein from Thermus thermophilus: analysis and comparison.
  229. (2003). Homotropic versus heterotopic cooperativity of cytochrome P450eryF: a substrate oxidation and spectral titration study. Drug Metab Dispos.
  230. (1999). Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors.
  231. (2000). How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms.
  232. (1999). How similar are P450s and what can their differences teach us,
  233. (2005). How to study proteins by circular dichroism.
  234. (2005). Human and rat liver cytochromes P450: functional markers, diagnostic inhibitor probes, and parameters frequently used in P450 studies. In:
  235. (1974). Human Mycobacterium-Ulcerans Infections Developing at Sites of Trauma to Skin.
  236. (1987). Identification and Characterization of 2 Functional Domains in Cytochrome-P-450Bm-3, a Catalytically Self-Sufficient Monooxygenase Induced by Barbiturates in Bacillus-Megaterium.
  237. (1999). Identification and characterization of IS2404 and IS2606: Two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR.
  238. (2000). Identification of a methyltransferase from Mycobacterium smegmatis involved in glycopeptidolipid synthesis.
  239. (2002). Identification of a new class of cytochrome P450 from a Rhodococcus sp.
  240. (1993). Identification of Charge-Transfer Transitions in the Optical-Spectrum of Low-Spin Ferric Cytochrome-P-450 Bacillus-Megaterium.
  241. (2001). Identification of genetic variants in the human thromboxane synthase gene (CYP5A1).
  242. (1995). Identification of Nitric-Oxide Synthase as a Thiolate-Ligated Heme Protein Using Magnetic Circular-Dichroism Spectroscopy -Comparison with Cytochrome P-450-Cam and Chloroperoxidase.
  243. (1999). Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility.
  244. (2003). Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans.
  245. (1998). Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P450 BM3.
  246. (1989). Immune mechanisms in the pathogenesis of pulmonary tuberculosis.
  247. (1982). Immunoreactive Substances of Mycobacteria.
  248. (2000). in The Porphyrin Handbook
  249. (2000). In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
  250. (2005). In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H(37)Rv. Fems Microbiology Letters.
  251. (2001). In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature.
  252. (2000). In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.
  253. (1998). In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother.
  254. (1999). Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope.
  255. (2002). Increasing the redox potential of isoform 1 of yeast cytochrome c through the modification of select haem interactions.
  256. (2007). Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines.
  257. (1993). Induction of Pulmonary Granulomas, Macrophage Procoagulant Activity, and Tumor-Necrosis-Factor-Alpha by Trehalose Glycolipids.
  258. (2001). Industrial biocatalysis today and tomorrow.
  259. (1986). Influence of Initial-Drug Resistance on the Response to Short-Course Chemotherapy of Pulmonary Tuberculosis. American Review of Respiratory Disease.
  260. (1990). Influences of Pi-Pi-Complex Formation, Dimerization, and Binding to Hemoglobin on the Planarity of Nickel(Ii) Porphyrins.
  261. (1987). Infrared and Raman spectra of metalloporphyrins.
  262. (1995). Inhibition of cytochrome P450 enzymes,
  263. (1989). Inhibition of Synthesis of Arabinogalactan by Ethambutol in Mycobacterium-Smegmatis. Antimicrobial Agents and Chemotherapy.
  264. (1993). Inhibitors of cytochrome P450 and possibilities for their therapeutic application, in Medicinal Implications
  265. (1997). Inhibitors of ergosterol biosynthesis as antifungal agents. Current Pharmaceutical Design.
  266. (1999). Insects in the transmission of Mycobacterium ulcerans infection.
  267. (2000). Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. Biochimica Et Biophysica ActaBioenergetics.
  268. (1985). Interlaboratory Drug Susceptibility Testing of Mycobacterium-Tuberculosis by a Radiometric Procedure and 2 Conventional Methods.
  269. (2007). Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages. Tuberculosis
  270. (1995). Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins.
  271. (2000). Iron metabolism in pathogenic bacteria. Annual review of microbiology.
  272. (1988). Isolation and identification of a morpholine-degrading bacterium.
  273. (1973). Isolation of Deoxyribonucleic Acid Methylase Mutants of Escherichia-Coli K-12.
  274. (2003). Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.
  275. (2001). Ketoconazoleinduced conformational changes in the active site of cytochrome P450eryF.
  276. (2005). Kinetic and binding studies with purified recombinant proteins ferredoxin reductase, ferredoxin and cytochrome P450 comprising the morpholine monooxygenase from Mycobacterium sp. strain HE5.
  277. (1994). Kinetic Solvent Isotope Effects during Oxygen Activation by Cytochrome P-450cam.
  278. (1997). Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.
  279. (1998). Lanosterol 14 alpha-demethylase (CYP51) and spermatogenesis. Drug Metabolism and Disposition.
  280. (1999). Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. Febs Letters.
  281. (1992). Lipoarabinomannan of Mycobacterium-Tuberculosis - Capping with Mannosyl Residues in Some Strains.
  282. (2003). Lipoarabinomannans: from structure to biosynthesis.
  283. (1991). Lipoprotein Antigens of Mycobacterium-Tuberculosis.
  284. (1983). Liver and Forestomach Tumors and Other Forestomach Lesions in Rats Treated with Morpholine and Sodium-Nitrite, with and without Sodium Ascorbate.
  285. (1991). Location of the mycolyl ester substituent in the cell walls of mycobacteria.
  286. (1999). Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
  287. (1981). Magnetic and Natural Circular-Dichroism Spectra of Cytochromes P-45011-Beta and P-450scc Purified from Bovine Adrenal-Cortex.
  288. (1991). Magnetic Circular-Dichroism of Hemoproteins.
  289. (1991). Magnetic Circular-Dichroism Spectroscopy as a Probe of Axial Heme Ligand Replacement in Semisynthetic Mutants of Cytochrome-C. Febs Letters.
  290. (1981). Magnetic Circular-Dichroism Studies of Cytochrome P-450cam Characterization of Axial Ligands of Ferric and Ferrous Low-Spin Complexes. Biochimica et biophysica acta.
  291. (1974). Magnetic Circular-Dichroism.
  292. (2001). Massive gene decay in the leprosy bacillus.
  293. (1992). Mechanisms of cytochrome P450 and peroxidase-catalyzed xenobiotic metabolism.
  294. (2004). Mechanisms of drug resistance in Mycobacterium tuberculosis.
  295. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
  296. (2001). Mechanisms of streptomycin resistance: Selection of mutations in the 16S rRNA gene conferring resistance. Antimicrobial Agents and Chemotherapy.
  297. (1994). Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium-Tuberculosis.
  298. (1987). Metalloporphyrin Core Size Resonance Raman Marker Bands Revisited - Implications for the Interpretation of Hemoglobin Photoproduct Raman Frequencies.
  299. (2001). Microbial pathogenesis of Mycobacterium tuberculosis: Dawn of a discipline.
  300. (1989). Microbial-Degradation of Nitrogen, Oxygen and Sulfur Heterocyclic-Compounds under Anaerobic Conditions - Studies with Aquifer Samples.
  301. (2005). Microbiology. TB--a new target, a new drug.
  302. (1999). Microspectrophotometric analysis of respiratory pigments using a novel fibre optic dip probe in microsamples.
  303. (2003). MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence.
  304. (1999). Modelling in Escherichia coli of mutations in mitoribosomal protein S12: novel mutant phenotypes of rpsL.
  305. (1998). Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
  306. (1991). Modular organization of genes required for complex polyketide biosynthesis.
  307. (2000). Modulation of redox potential in electron transfer proteins: effects of complex formation on the active site microenvironment of cytochrome b5. Faraday discussions,
  308. (1998). Modulation of the redox potentials of FMN in Desulfovibrio vulgaris flavodoxin: Thermodynamic properties and crystal structures of glycine-61 mutants.
  309. (1999). Molecular aspects of azole antifungal action and resistance. Drug Resist Updat.
  310. (1996). Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid.
  311. (1998). Molecular basis of P450 inhibition and activation -Implications for drug development and drug therapy. Drug Metabolism and Disposition.
  312. (1989). Molecular Cloning, a laboratory manual, 2nd Edition,
  313. (2004). Molecular cloning, nucleotide sequencing and expression of genes encoding a cytochrome P450 system involved in secondary amine utilization in Mycobacterium sp. strain RP1.
  314. (1998). Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis:
  315. (1997). Molecular mechanisms of azole resistance in fungi.
  316. (1993). Molecular Recognition in Cytochrome-P-450 - Mechanism for the Control of Uncoupling Reactions.
  317. (1994). MolecularCloning and Expression of Human Prostacyclin Synthase.
  318. (1998). Morpholine degradation pathway of Mycobacterium aurum MO1: direct evidence of intermediates by in situ 1H nuclear magnetic resonance. Applied and environmental microbiology.
  319. (1973). Mossbauer studies of cytochrome P-450 cam.
  320. (1998). Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis.
  321. (1993). Multidrug-resistant tuberculosis and its control.
  322. (1995). Multidrug-Resistant Tuberculosis in Patients without HIV-Infection.
  323. (1992). Multidrug-resistant tuberculosis.
  324. (1998). Multiple activated oxygen species in P450 catalysis - Contributions to specificity in drug metabolism.
  325. (1992). Mutant Sequences in the Rpsl Gene of Escherichia-Coli B/R - Mechanistic Implications for Spontaneous and Ultraviolet-Light Mutagenesis. Molecular and General Genetics.
  326. (1996). Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.
  327. (2000). Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.
  328. (2000). Mutations of phenylalanine-193 in the putative substrate access channel alter the substrate specificity of cytochrome P450(cam).
  329. (1998). Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects.
  330. (2003). Mycobacterial porins--new channel proteins in unique outer membranes.
  331. (1996). Mycobacterium hodleri sp. nov., a new member of the fast-growing mycobacteria capable of degrading polycyclic aromatic hydrocarbons.
  332. (2004). Mycobacterium tuberculosis cell envelope lipids and the host immune response.
  333. (2004). Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health.
  334. (2005). Mycobacterium ulcerans disease.
  335. (2001). Mycobacterium ulcerans in wild animals.
  336. Mycobacterium ulcerans infection.
  337. (1977). Mycobacterium-Smegmatis Fatty-Acid Synthetase - LongChain Transacylase Chain-Length Specificity.
  338. (1999). Mycolactone: A polyketide toxin from Mycobacterium ulcerans required for virulence.
  339. (1998). Mycolic acids: structure, biosynthesis and physiological functions.
  340. (1984). N-nitrosamine formation by intestinal bacteria.
  341. (1995). NADPH oxidase activity of cytochrome P-450 BM3 and its constituent reductase domain. Biochimica et biophysica acta.
  342. (1976). Naturally occurring nitrosatable amines. II. Secondary amines in tobacco and cigarette smoke condensate.
  343. (2002). New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen.
  344. (1998). New tuberculosis drug development - How can we do better?
  345. (1985). Nitrocellulose-Based Assays for the Detection of Glycolipids and Other Antigens - Mechanism of Binding to Nitrocellulose.
  346. (1996). Nonplanar distortions of nickel(II) dialkylporphyrins along combinations of the lowest-frequency out-of-plane normal coordinates.
  347. (1998). Nonplanar porphyrins and their significance in proteins.
  348. (2001). Novel heme ligation in a c-type cytochrome involved in thiosulfate oxidation:
  349. (1977). Novel Method for Investigation of Electrochemistry of Metalloproteins -
  350. (2000). On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics - Towards the prediction of human P450 substrate specificity and metabolism.
  351. (1995). Organization (WHO)
  352. Organization. (2001)Global tuberculosis control: WHO report.
  353. (1996). Outcome of MDR-TB patients, 1983-1993 - Prolonged survival with appropriate therapy.
  354. (1980). Oxygen Activation by Cytochrome-P-450. Annual Review of Biochemistry.
  355. (1996). P450s: structural similarities and functional differences.
  356. (2005). Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis.
  357. (2000). Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.
  358. (2001). Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450BM3.
  359. (2003). Phosphoinositide recognition domains.
  360. (2004). Phylogeny of Mycobacterium avium strains inferred from glycopeptidolipid biosynthesis pathway genes.
  361. (2006). Physiological, biochemical, and genetic characterization of an alicyclic amine-degrading Mycobacterium sp. strain THO100 isolated from a morpholine-containing culture of activated sewage sludge.
  362. (1958). Pigments of Rat Liver Microsomes.
  363. (2001). Polyketide biosynthesis: a millennium review.
  364. (1993). Polyketide synthesis: prospects for hybrid antibiotics.
  365. (2000). Polyprenyl phosphate biosynthesis in Mycobacterium tuberculosis and Mycobacterium smegmatis.
  366. (1991). Postulated epidemiology of Mycobacterium ulcerans infection.
  367. (2003). Preliminary characterisation and crystal structure of a thermostable cytochrome P450 from Thermus thermophilus,
  368. (1965). Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis.
  369. (2001). Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Seminars in cell and developmental biology.
  370. (1976). Prevention of PhagosomeLysosome Fusion in Cultured Macrophages by Sulfatides of Mycobacterium-Tuberculosis.
  371. (1991). Principles of IUATLD collaborative tuberculosis progammes. Bull Int Union Tuberc Lung Dis.
  372. (1996). Probing ng the heme iron coordination structure of pressure-induced cytochrome P420(cam).
  373. (2001). Probing the open state of cytochrome P450cam with ruthenium-linker substrates.
  374. (1987). Production of single-stranded plasmid DNA,
  375. (2004). Programmes and principles in treatment of multidrug-resistant tuberculosis.
  376. (2002). Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).
  377. (2007). Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
  378. (2001). Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer.
  379. (1983). Protein Blotting - Principles and Applications. Analytical Biochemistry.
  380. (2000). Protein engineering of cytochromes P-450. Biochimica Et Biophysica Acta-Protein Structure and Molecular Enzymology.
  381. (2002). Protein lipid overlay assay.
  382. (2003). Protein side-chain motion and hydration in protontransfer pathways. Results for cytochrome P450cam.
  383. (1976). Purification and Characterization of Adrenal-Cortex Mitochondrial Cytochrome-P-450 Specific for Cholesterol Side-Chain Cleavage Activity.
  384. (2000). Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
  385. (1967). Pyrazinamide Susceptibility and Amidase Activity of Tubercle Bacilli.
  386. (1997). Pyruvate formate-lyase activating enzyme is an iron-sulfur protein.
  387. (1981). Rapid Drug-Susceptibility Testing of MycobacteriumTuberculosis. American Review of Respiratory Disease.
  388. (2007). Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium. The Journal of biological chemistry.
  389. (1982). Rapid Susceptibility Testing of Mycobacterium-Tuberculosis by a Radiometric Technique.
  390. (1999). Rational 'DOTS Plus' for the control of MDR-TB.
  391. (2002). Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv.
  392. (1994). Recognition of the Lipid Intermediate for Arabinogalactan Arabinomannan Biosynthesis and Its Relation to the Mode of Action of Ethambutol on Mycobacteria.
  393. (1979). Recognition Sequence of the Dam Methylase of EscherichiaColi-K12 and Mode of Cleavage of Dpn-I Endonuclease.
  394. (2001). Recognizing phosphatidylinositol 3-phosphate.
  395. (1997). Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid.
  396. (1978). Redox potentiometry: determination of midpoint potentials of oxidationreduction components of biological electron transfer systems.
  397. (2006). Regioselective hydroxylation of adamantane by Streptomyces griseoplanus cells.
  398. (1984). Regioselectivity in the cytochromes P-450: control by protein constraints and by chemical reactivities.
  399. (1993). Resistance of Candida-Albicans to Azole Antifungal Agents.
  400. (2005). Resolution of two substrate-binding sites in an engineered cytochrome P450eryF bearing a fluorescent probe.
  401. (2002). Resonance Raman and ligand binding studies of the oxygen-sensing signal transducer protein HemAT from Bacillus subtilis.
  402. (2002). Resonance Raman evidence for protein-induced out-ofplane distortion of the heme prosthetic group of mammalian lactoperoxidase.
  403. (1979). Resonance Raman spectroscopy,
  404. (1978). Resonance Raman-Spectra of Octaethylporphyrinato-Ni(Ii) and Meso-Deuterated and N-15 Substituted Derivatives .2. Normal Coordinate Analysis.
  405. (1977). Reversible Electrode-Reaction of Cytochrome-C.
  406. (2002). Review of the safety and efficacy of voriconazole.
  407. (1972). Rifampicin in Experimental Mycobacterium-Ulcerans Infection.
  408. (2005). Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis.
  409. (1999). Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
  410. (2000). Role of individual drugs in the chemotherapy of tuberculosis.
  411. (2004). Role of neighboring FMN side chains in the modulation of flavin reduction Potentials and in the energetics of the FMN: Apoprotein interaction in Anabaena flavodoxin.
  412. (2000). Role of the heme active site and protein environment in structure, spectra and function of the cytochrome P450s, Chemical Reviews.
  413. (1997). Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.
  414. (2004). Role of Tyr-288 at the dioxygen reduction site of cytochrome bo studied by stable isotope labeling and resonance Raman spectroscopy.
  415. (1999). Roles of key active-site residues in flavocytochrome P450 BM3.
  416. (1989). Ruffling of Nickel(Ii) Octaethylporphyrin in Solution.
  417. (2007). Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.
  418. (1987). Simultaneous determination of hemes a,b, and c from pyridine hemochrome spectra. Analytical Biochemistry.
  419. (2003). Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy.
  420. (2002). Site-directed mutagenesis of cytochrome P450eryF: Implications for substrate oxidation, cooperativity, and topology of the active site.
  421. (1996). Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: Effects on catalase-peroxidase activities and isoniazid resistance.
  422. (2005). Sites of covalent attachment of CYP4 enzymes to heme: evidence for microheterogeneity of P450 heme orientation.
  423. (2005). Slow growth rate of mycobacteria. Possible reasons and significance for their pathogenicity.
  424. (2003). Society, CDC and Infectious Diseases Society of America
  425. (1982). Spectroscopic Investigations of Ferric Cytochrome P-450-Cam Ligand Complexes - Identification of the Ligand Trans to Cysteinate in the Native Enzyme.
  426. (1978). Sterilizing Value of Rifampicin and Pyrazinamide in Experimental Short Course Chemotherapy.
  427. (1996). Sterol 14-demethylase P450 (P45014DM*) is one of the most ancient and conserved P450 species.
  428. (1991). Sterol biosynthesis inhibitors: their current status and modes of action.
  429. (1994). Streptomycin resistance in mycobacteria.
  430. (2005). Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria.
  431. (2001). Structural and spectroscopic analysis of the F393H mutant of flavocytochrome P450 BM3.
  432. (2004). Structural aspects of ligand binding to and electron transfer in bacterial and fungal P450s. Annu Rev Biochem.
  433. (1992). Structural Basis of Capacity of Lipoarabinomannan to Induce Secretion of Tumor-Necrosis-Factor.
  434. (1995). Structural Domains of P450-Containing Monooxygenase Systems.
  435. (1991). Structural Features of the Arabinan Component of the Lipoarabinomannan of Mycobacterium-Tuberculosis.
  436. (1996). Structural flexibility and functional versatility of mammalian P450 enzymes.
  437. (1993). Structural Heterogeneity of Octaethylporphyrins Probed by Resonance Raman-Spectroscopy.
  438. (2000). Structural similarities and differences of the heme pockets of various P450 isoforms as revealed by resonance Raman spectroscopy.
  439. (1995). Structural studies on prokaryotic cytochromes
  440. (2002). Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae - Presence of unusual components with alpha 1,3-mannopyranose side chains.
  441. (1993). Structure and Antigenicity of Lipoarabinomannan from Mycobacterium-Bovis Bcg.
  442. (2005). Structure and chemistry of cytochrome P450. Chem Rev.
  443. (2004). Structure and direct electrochemistry of cytochrome P450 from the thermoacidophilic crenarchaeon, Sulfolobus tokodaii strain 7.
  444. (1995). Structure and function of cytochromes P450: a comparative analysis of three crystal structures.
  445. (2005). Structure elucidation of a novel family of mycolactone toxins from the frog pathogen Mycobacterium sp. MU128FXT by mass spectrometry.
  446. (2003). Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14 alpha-demethylase of fungi.
  447. (1998). Structure-function of cytochromes P450 and flavin-containing monooxygenases -Implications for drug metabolism. Drug Metabolism and Disposition.
  448. (1980). Structure-function relations in flavodoxins.
  449. (2003). Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis.
  450. (1999). Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.
  451. (2000). Substrate binding to 15 beta-hydroxylase (CYP106A2) probed by FT infrared spectroscopic studies of the iron ligand CO stretch vibration.
  452. (2003). Substrate recognition and molecular mechanism of fatty acid hydroxylation by cytochrome P450 from Bacillus subtilis - Crystallographic, spectroscopic, and mutational studies.
  453. (1992). Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.
  454. (1992). Substrate Recognition Sites in Cytochrome-P450 Family-2 (Cyp2) Proteins Inferred from Comparative Analyses of Amino-Acid and Coding Nucleotide-Sequences.
  455. (1989). Substrate-Specificity and Affinity of a Protein Modulated by Bound Water-Molecules.
  456. (2003). Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans.
  457. (2003). Super bugs' for bioremediation.
  458. (1991). Surface-Enhanced Resonance Raman-Scattering from Cytochromes-P-450 Adsorbed on Citrate-Reduced Silver Sols.
  459. (2003). Surface-exposed glycopeptidolipids of Mycobacterium smegmatis specifically inhibit the phagocytosis of mycobacteria by human macrophages - Identification of a novel family of glycopeptidolipids.
  460. (1989). Survey of microbial oxygenases: trichloroethylene degradation by propane-oxidizing bacteria.
  461. (2001). Suspension cultivation of Mycobacterium ulcerans for the production of mycolactones.
  462. (2002). Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.
  463. (2003). The 1.92-angstrom structure of Streptomyces coelicolor A3(2) CYP154C1 - A new monooxygenase that functionalizes macrolide ring systems
  464. (2003). The 1.92-angstrom structure of Streptomyces coelicolor A3(2) CYP154C1 - A new monooxygenase that functionalizes macrolide ring systems.
  465. (1994). The biodegradation of piperazine and structurally-related linear and cyclic amines.
  466. (1995). The Biosynthesis of Cyclopropanated Mycolic Acids in Mycobacterium tuberculosis - Identification and FunctionalAnalysis of Cmas-2.
  467. (1992). The Catalase Peroxidase Gene and Isoniazid Resistance of Mycobacterium-Tuberculosis.
  468. (2000). The catalytic pathway of cytochrome P450cam at atomic resolution,
  469. (1997). The complete genome sequence of Escherichia coli K-12.
  470. (2003). The complete genome sequence of Mycobacterium bovis.
  471. (1997). The complete genome sequence of the Gram-positive bacterium Bacillus subtilis.
  472. (2002). The cytochrome p450 complement (CYPome) of Streptomyces coelicolor A3(2).
  473. (1983). The diverse spectroscopic properties of ferrous cytochrome P-450-CAM ligand complexes.
  474. (1986). The Effect of Gamma-Radiation on Biodegradability of Morpholine in Aqueous-Solution.
  475. (1990). The Effect of Withdrawal of Morpholine from the Influent and Its Reinstatement on the Performance and Microbial Ecology of a Model Activated-Sludge Plant Treating a Morpholine-Containing Influent.
  476. (1997). The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.
  477. (1998). The envelope layers of mycobacteria with reference to their pathogenicity.
  478. (1995). The Envelope of Mycobacteria.
  479. (1955). The Enzymatic Demethylation of Ephedrine.
  480. (2007). The evolutionary history of cytochrome P450 genes in four filamentous Ascomycetes.
  481. (2000). The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis.
  482. (2000). The genome sequence of Mycobacterium tuberculosis reveals cytochromes P450 as novel anti-TB drug targets.
  483. (2003). The global situation of MDR-TB.
  484. (1998). The great diversity of reactions catalyzed by cytochromes P450. Comparative Biochemistry and Physiology C-Toxicology and Pharmacology.
  485. (1990). The historical decline of tuberculosis in Europe and America: its causes and significance.
  486. (1993). The Hydrolytic Water Molecule in Trypsin, Revealed by Time-Resolved Laue Crystallography.
  487. (1986). The immunology of mycobacterial diseases. Am Rev Respir Dis.
  488. (2007). The ins and outs of cytochrome P450s.
  489. (1982). The Microbial-Degradation of Morpholine.
  490. (1998). The Mycobacterium tuberculosis genomic sequence: anatomy of a master adaptor.
  491. (2001). The Mycobacterium tuberculosis pks2 gene encodes the synthase for the hepta- and octamethylbranched fatty acids required for sulfolipid synthesis.
  492. (1982). The Mycolic Acids of Mycobacterium chelonei.
  493. (2001). The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.
  494. (1971). The origin of the heme Cotton effects in myoglobin and hemoglobin.
  495. (2005). The pathogenesis of tuberculosis - The first one hundred (and twentythree) years.
  496. (2000). The Protein Data Bank.
  497. (2001). The Raman Effect: A Large-Scale Lecture Demonstration.
  498. (1996). The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis.
  499. (1988). The Role of Pyrazinamide in Tuberculosis Chemotherapy.
  500. (1995). The role of Thr268 in oxygen activation of cytochrome P450BM-3.
  501. (1988). The Roles of Active-Site Hydrogen-Bonding in Cytochrome P-450Cam as Revealed by Site-Directed Mutagenesis.
  502. (2000). The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages.
  503. (2005). The structural biology of type II fatty acid biosynthesis.
  504. (1997). The structure of the cytochrome P450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid.
  505. (1999). The theory of X-ray diffraction by a crystal. Principles of Protein X-ray Crystallography, 2nd edn.
  506. (1991). The Transformation of Heterocyclic Aromatic-Compounds and Their Derivatives under Anaerobic Conditions. Critical Reviews in Environmental Control.
  507. (1995). The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties.
  508. (2004). The vitro efficacy of beta-lactam and betalactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
  509. (2004). Thermodynamic and biophysical characterization of cytochrome p450 BioI from Bacillus subtilis.
  510. (1989). Topological distribution of four-alpha-helix bundles.
  511. (1994). Transfer of polychlorophenol-degrading Rhodococcus chlorophenolicus (Apajalahti et al.
  512. (1994). Transmission of Tuberculosis in New-York-City - an Analysis by DNAFingerprinting and Conventional Epidemiologic Methods. New England
  513. (1999). Treatment and prevention of multidrug-resistant tuberculosis.
  514. (1994). Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children.
  515. (2000). Trehalose 6,6 '-dimycolate (cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages. Infection and Immunity.
  516. (2000). Trehalose 6,6 '-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats.
  517. (1998). Tuberculosis and HIV infection: a global perspective.
  518. (1996). Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis.
  519. (2004). Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect Dis.
  520. (1995). Twenty-five years of P450cam research: mechanistic insights into oxygenase catalysis,
  521. (1989). Uncoupling of the Cytochrome P-450Cam Monooxygenase Reaction by a Single Mutation, Threonine-252 to Alanine or Valine - a Possible Role of the Hydroxy AminoAcid in Oxygen Activation.
  522. (1998). Understanding heme cavity structure of peroxidases: Comparison of electronic absorption and resonance Raman spectra with crystallographic results.
  523. (1992). Understanding the Chemotherapy of Tuberculosis - Current Problems.
  524. (1998). Understanding the role of the essential Asp251 in cytochrome P450cam using site-directed mutagenesis, crystallography, and kinetic solvent isotope effect.
  525. (2003). Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans.
  526. (1986). Use of a bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.
  527. (1998). Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.
  528. (1995). Utilization of Solubilized and Crystalline Mixtures of Polycyclic Aromatic-Hydrocarbons by a Mycobacterium Sp.
  529. (1988). UV resonance Raman studies of molecular structure and dynamics: applications in physical and biophysical chemistry. Annual review of physical chemistry.
  530. (1999). UV-visible spectroscopy as a tool to measure flavoproteins in Flavoprotein Protocols
  531. (1996). Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates.
  532. (1989). Variational theory for g tensor in electron paramagnetic resonance experiments: application to ferricytochrome c and azidomyoglobin.
  533. (1982). Vinyl Influences on Protoheme Resonance Raman-Spectra - Nickel(Ii) Protoporphyrin-Ix with Deuterated Vinyl Groups.
  534. (2002). Voriconazole - Better chances for patients with invasive mycoses.
  535. (1991). Water-Structure in Cubic Insulin Crystals.
  536. (1999). Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.
  537. (1998). World Health Organisation targets untreatable ulcer: report from the first international conference on Buruli ulcer control and research, Inter Press Service,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.